Add glucagon to a weight loss drug and you burn more fat. That is the pitch on every peptide forum I get asked about, and mechanistically it sounds reasonable: glucagon raises energy expenditure and drives fat oxidation, so retatrutide, which adds a glucagon receptor to the two that tirzepatide already hits, should strip fat and spare muscle better than anything before it.
The published body composition data say the opposite. In the trials, retatrutide loses roughly 35 percent of its weight as lean mass. Tirzepatide loses about 25 percent. Worse ratio, for the drug that was supposed to be metabolically smarter.
I am writing this because retatrutide is not FDA approved for anything, and the confident claims about it online have completely outrun what the studies can defend. If you are going to consider a molecule this powerful, you deserve better than someone’s before-and-after photo.
What retatrutide actually is
Retatrutide (Eli Lilly’s LY3437943) is a single peptide that activates three receptors at once: GLP-1 and GIP, the two tirzepatide hits, plus the glucagon receptor. That third target is the reason it exists. GLP-1 and GIP suppress appetite and improve insulin response. Glucagon, in theory, adds a push on energy expenditure and fat oxidation on top.
On raw weight loss, it delivers. The phase 2 obesity trial (Jastreboff and colleagues, New England Journal of Medicine, 2023) produced about 24 percent weight loss at 48 weeks, the largest figure the incretin class had recorded. In May 2026, Lilly reported topline results from TRIUMPH-1, the pivotal phase 3 obesity trial in 2,339 patients: roughly 28 percent average weight loss at 80 weeks, territory we usually associate with bariatric surgery.
Here is what the forums skip. Retatrutide is still investigational. It is not approved by the FDA or any major regulator, the phase 3 program is still reading out through 2026, and Lilly is not expected to file its application until late 2026 at the earliest. Every gram being injected outside a clinical trial today comes from a compounding pharmacy or the grey market, without the monitoring the trials are built to provide.
The glucagon promise and what body composition data show
Weight on a scale is not the number that matters. What matters is what you lose. Drop 20 percent of your body weight and you want that to be fat, not the muscle that carries you up the stairs at 75.
The most detailed retatrutide data come from a DXA substudy of its phase 2 diabetes trial (Coskun and colleagues, Lancet Diabetes and Endocrinology, 2025). Across the 4 to 12 mg doses, about 65 percent of the weight lost was fat and 35 percent was lean tissue. At 8 mg, patients lost up to 6.5 kg of lean mass. The ratio got slightly worse at higher doses, not better.
Tirzepatide’s DXA substudy from SURMOUNT-1 (Look and colleagues, Diabetes, Obesity and Metabolism, 2025) landed at about 75 percent fat, 25 percent lean, and that split held across age, sex, and how much weight people lost. Its fat-to-lean ratio improved from 0.93 to 0.70 over 72 weeks. Composition got better, not just lighter.
The honest caveat, because this is exactly what gets flattened online: these are two different trials, not a head-to-head. Retatrutide’s data are in people with type 2 diabetes over 36 weeks; tirzepatide’s are in people without diabetes over 72 weeks. The glucagon component is one plausible explanation for the wider lean loss, not a proven one.
But notice what did not happen. The drug built around a fat-oxidation hormone did not produce a better fat-to-lean ratio. A 2026 systematic review in Annals of Internal Medicine frames it well: across incretin therapies, the median share of weight lost as lean mass was about 28 percent, and two-thirds of studies crossed 25 percent. Retatrutide sits at the higher end of a range that is already higher than most people think.
Why the muscle loss, and the glucagon question nobody asks
There is a mechanistic reason to take this seriously rather than wave it off. Chronic glucagon receptor activation can lower circulating amino acids and blunt muscle protein synthesis. In plain terms, the same hormone sold as the fat-burning upgrade may quietly make it harder to hold onto muscle. A hypothesis, not a verdict, but it fits the direction of the data.
Then there is the question I almost never see raised in the enthusiasm: glucagon resistance. Hit any receptor hard enough for long enough and the body tends to downregulate it. If sustained glucagon agonism makes the target tissues less responsive over time, the fat-oxidation benefit that justifies the third receptor could fade while the appetite suppression carries on. We have no long-term human data to confirm or rule that out. Anyone telling you how retatrutide behaves at year three is guessing.
The phase 2 program also flagged dose-related cutaneous sensory symptoms, a skin sensitivity most people have never heard of because it does not show up in a transformation photo. I raise it not to alarm you but to make a point: the trials keep surfacing effects the marketing does not mention. That is what trials are for.
What FDA approval will and will not mean
Retatrutide will probably be approved. The phase 3 data are strong and the filing is coming. When it happens, expect a wave of posts treating approval as a finish line, as proof the drug is safe and the argument is settled.
That is not what approval means. FDA approval means a molecule has been studied thoroughly enough that we understand its benefits and its harms well enough to make an informed decision. It is a statement about the quality of the evidence, not a blessing. Approved drugs carry real risks. We accept them because those risks have been measured and weighed against the benefit in thousands of people.
That distinction is the whole point here. Right now retatrutide has none of that for the person buying it from a compounding pharmacy: no approved dose, no monitoring plan, no labeled contraindications, no post-market surveillance catching the rare event a 2,000-person trial missed. You are not getting the drug that gets approved in 2027. You are getting the same molecule stripped of everything that makes approval mean something.
If you are going to experiment on yourself
I am not going to pretend nobody will use this before 2027. People are using it now. So here is the version of this conversation that actually helps.
Get qualified information first, not forum consensus. Read the trials, or work with someone who has. Assume the lean mass loss is real and plan around it. The two best-supported tools for preserving muscle during weight loss are not exotic: resistance training at least twice a week, and adequate protein, roughly 1.6 grams per kilogram of body weight per day for most people losing weight. A 2025 joint advisory from the American College of Lifestyle Medicine and several nutrition and obesity societies (American Journal of Clinical Nutrition) says essentially the same thing for anyone on incretin therapy. This is the core of how I approach metabolic optimization with patients: measure body composition, protect muscle, and treat the drug as one input rather than the whole plan.
Measure, do not assume. A scale cannot tell you whether you are losing fat or muscle. A DXA scan can, and repeating one during treatment turns guesswork into data. Do it with a physician who can screen you for contraindications you may not know you have. That is the difference between an experiment and a gamble.
Frequently asked questions
Q: Is retatrutide better than Ozempic or Mounjaro? A: On weight loss alone, the trial numbers are higher, roughly 24 to 28 percent versus about 15 to 21 percent for the approved drugs. But it is not approved, has no long-term safety record, and appears to cost you slightly more lean mass along the way. A bigger number on the scale and a better choice for you are not the same question.
Q: Can I get retatrutide legally right now? A: Not as an approved prescription. It is sold through compounding pharmacies and research-peptide vendors that operate in a legal grey area without the oversight of a real prescription. If you go that route, you are accepting that no regulator has verified what is actually in the vial.
Q: Should I wait until it is approved? A: For most people, yes. Approval will bring dosing guidance, a known side effect profile, and monitoring that does not exist for the compounded version today. Waiting means getting the drug with its safety infrastructure attached, which is most of what you are paying for anyway.
Where to start
If you are weighing a drug like this, the useful conversation is not with a forum or a compounding pharmacy’s order page. It is with a physician who will look at your labs, measure your body composition, and tell you plainly whether it fits your situation, including when the answer is not yet.
That kind of unhurried, evidence-first conversation is what membership at Elite Medical Associates is built for. If you want to explore whether it is the right fit, start with a complimentary inquiry call: no pitch, just a straight discussion of what you are trying to do and whether we are the right people to help. elitemedlv.com
Sources
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389:514-526.
- Coskun T, et al. Effects of Retatrutide on Body Composition in People With Type 2 Diabetes: A Substudy of a Phase 2 Trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684.
- Look M, et al. Body Composition Changes During Weight Reduction With Tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025;27(5):2720-2729.
- Batsis JA, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Ann Intern Med. 2026.
- Mozaffarian D, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory. Am J Clin Nutr. 2025;122(1):344-367.
- Eli Lilly. TRIUMPH-1 Phase 3 topline results. May 21, 2026.